Emas Pharma was originally formed in 1998 to support US pharma companies looking to work across Europe. 11 years later in 2009, Bionical was established as a Clinical Trial Supply business serving the global pharma and biotech industry.
The two organizations subsequently merged in 2016 to broaden service offerings and strengthen it’s global footprint. In 2018, Bionical Emas proudly founded the Early Access Programs division, giving a unique opportunity to help patients around the world gain access to life-changing medicines.
In December 2024, Bionical Emas sold its Clinical Development division to allow the Company to further specialize, with a clear vision to become the number one Early Access Programs (EAP) and Clinical Trial Supply (CTS) provider in the world.